Drugs / CL-197
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05944848 | Nov 2022 → Jan 2024 | — | Henan Genuine Biotech Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07308782 | Nov 2025 → Dec 2026 expected | HIV infectious disease | Henan Genuine Biotech Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CL-197 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07308782 ↗ |
| Route | Oral | “Single oral dose of 1 mg CL-197 capsules” NCT05944848 ↗ |